Terence Flynn

just was wondering if you have any update in terms of how to think about the design of the Type II diabetes CVOT trial, particularly the control arm

maybe you could walk us through some of the puts and takes that we should think about heading into 2026.

how you're thinking about the design of MariTide CVOT study in type 2 diabetes in light of Eli Lilly's recent SURPASS-CVOT data

if you could help frame for us what we should be looking for at ADA with respect to MariTide. I know it's going to be the first detailed the Phase II data.

I know you're doing part 2 of the Phase II to explore quarterly dosing. Just wondering if there's an interim look there so you can incorporate that schedule into the Phase III program

just wondering if you can comment at all high level about how we should think about overall PrEP market growth

just wondering how durable this kind of a growth rate is given what you're seeing out there in the market

you added MRD negativity as a co-primary endpoint in the anetocel Phase III trial

I just wanted to understand what is included, if anything at all for len for PReP in the '25 revenue guide

I'm assuming we should assume that this is kind of the steady-state level as we think about the forward into '26 as well

I was wondering, post a lot of the earlier stage data, earlier line data we've seen for TechValley, if you could speak to how you're thinking about positioning here of that franchise relative to Ca...

I know at our healthcare conference you talked about some upcoming data you're going to have for your anti-tau antibody

You mentioned oncology target of $50 billion by end of the decade. It looks like that's well above consensus

just wondering if that's based on your impression of the most likely outcome here or that's more just your speculation or hope

how you're thinking about that, both from the bispecifics as well as CAR-T and maybe a broadening into the community setting

Just wondering if you can talk about what's embedded for Medicare volume ramp in the back half of the year and how that might drive the range we're seeing on the revenue side

I was surprised that it wasn't on the first list of the Commissioner's National Priority Review Voucher program. And so maybe you could just comment on kind of if you guys are seeking that voucher

if you can just frame expectations for us down for the upcoming ATTAIN-2 Phase III data

if you're delivering the same profile as an injectable medicine, why would you decide to price lower

if you could maybe elaborate on your expectations for Zepbound payer dynamics and access this year, particularly the impact from the OSA label

if you can give us any comments on the top line in terms of some of the pushes and pulls as we think about that

I was just wondering if you could help frame for us the potential impact there

Was just wondering if the change in outer-year GARDASIL sales impacts at all how you're thinking about